Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-0.52 Insider Own0.30% Shs Outstand216.15M Perf Week-2.04%
Market Cap13.89B Forward P/E30.35 EPS next Y2.12 Insider Trans-7.24% Shs Float211.77M Perf Month-1.18%
Income-109.20M PEG- EPS next Q0.48 Inst Own94.10% Short Float2.48% Perf Quarter-5.25%
Sales1.80B P/S7.73 EPS this Y-385.10% Inst Trans-1.66% Short Ratio3.45 Perf Half Y-11.95%
Book/sh8.48 P/B7.58 EPS next Y92.63% ROA-4.60% Target Price83.67 Perf Year-33.35%
Cash/sh6.36 P/C10.10 EPS next 5Y31.09% ROE-6.40% 52W Range58.33 - 102.63 Perf YTD-32.15%
Dividend- P/FCF155.02 EPS past 5Y-35.00% ROI-14.80% 52W High-37.39% Beta0.95
Dividend %- Quick Ratio4.00 Sales past 5Y38.90% Gross Margin95.90% 52W Low10.17% ATR2.58
Employees1208 Current Ratio4.00 Sales Q/Q17.90% Oper. Margin-4.70% RSI (14)46.27 Volatility3.63% 3.77%
OptionableYes Debt/Eq0.01 EPS Q/Q-20.30% Profit Margin-6.10% Rel Volume1.11 Prev Close64.82
ShortableYes LT Debt/Eq0.01 EarningsJan 29 BMO Payout- Avg Volume1.52M Price64.26
Recom2.20 SMA20-2.11% SMA50-1.43% SMA200-7.71% Volume1,697,059 Change-0.86%
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-11-18Upgrade Evercore ISI In-line → Outperform
Apr-09-18Reiterated Credit Suisse Outperform $145 → $78
Apr-09-18Downgrade Gabelli & Co Buy → Hold
Apr-06-18Downgrade William Blair Outperform → Mkt Perform
Apr-06-18Downgrade Guggenheim Buy → Neutral
Apr-05-18Reiterated Barclays Overweight $165 → $135
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Dec-18-18 09:37AM  Here Are Biotechs Big Pipeline Disappointments in 2018 Motley Fool
09:24AM  Immuno-Oncology Suffered a Setback in 2018. Whats Next? Motley Fool
Dec-17-18 02:53PM  Incyte (INCY) Collaborates with Innovent for 3 Candidates Zacks
09:44AM  Incyte enters into potential $391M collaboration with Chinese biopharm firm American City Business Journals
Dec-16-18 08:22PM  Innovent, Incyte Announce Strategic Collaboration, Licensing Agreement for Three Clinical-stage Product Candidates in China; Incyte to Receive $40M Upfront; Up to $331M in Regulatory and Commercial Milestones Benzinga
05:48PM  BRIEF-Innovent, Incyte Announce Strategic Collaboration And Licensing Agreement Reuters
05:40PM  Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China Business Wire
05:35PM  Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China PR Newswire
Dec-14-18 10:50AM  Global fears strike Wall Street Yahoo Finance
07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
Dec-13-18 10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
08:00AM  Incyte to Present at Upcoming Investor Conferences Business Wire
06:45AM  FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE) PR Newswire
Dec-12-18 08:56AM  Roche to Create Companion Diagnostic Test for Merck's Keytruda Zacks
Dec-10-18 03:45PM  Why MacroGenics Stock Is Getting Hammered Today Motley Fool
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
Dec-04-18 05:25PM  Incyte (INCY) Announces Positive Data on Jakafi for GVHD Zacks
07:00AM  Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals ACCESSWIRE
Dec-03-18 10:00AM  Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit Business Wire +6.33%
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
Nov-29-18 09:31AM  Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report? Zacks
Nov-27-18 07:30AM  Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer Business Wire
Nov-23-18 09:10AM  A Look At The Intrinsic Value Of Incyte Corporation (NASDAQ:INCY) Simply Wall St.
Nov-21-18 04:19PM  This Highly Rated Pharma Giant Is More Than Just A Diabetes Player Investor's Business Daily
Nov-19-18 09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
Nov-15-18 10:01AM  Merck's Keytruda Improves Survival in Esophageal Cancer Study Zacks
Nov-07-18 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Nov-05-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive New Research Emphasizes Economic Growth GlobeNewswire
Nov-02-18 11:15AM  Incyte's Shares Have Taken a Beating in 2018 -- Here's Why Motley Fool
Nov-01-18 08:21PM  Scary Markets, Frightening Stocks, and How to Keep From Panicking Motley Fool +5.57%
11:06AM  Edited Transcript of INCY earnings conference call or presentation 30-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
10:36AM  Multiple Abstracts Highlighting Data from Incytes Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting Business Wire
08:23AM  3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte InvestorPlace
08:00AM  Today's Research Reports on Trending Tickers: Agios Pharmaceuticals and Incyte ACCESSWIRE
Oct-30-18 03:09PM  Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:45PM  Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View Zacks
08:30AM  Incyte (INCY) Misses Q3 Earnings and Revenue Estimates Zacks
07:26AM  Incyte: 3Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Third Quarter and Nine Month Financial Results and Provides Updates on Key Clinical Programs Business Wire
Oct-28-18 09:33AM  Better Buy: Vertex Pharmaceuticals Incorporated vs. Incyte Corporation Motley Fool
Oct-25-18 02:14PM  Incyte Named a 2018 Top Employer by Science Magazine Business Wire +5.53%
07:30AM  FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease Business Wire
Oct-24-18 04:49PM  Incyte (INCY) to Report Q3 Earnings: What's in the Cards? Zacks -6.33%
11:19AM  Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod Zacks
Oct-21-18 06:30PM  ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis PR Newswire
06:45AM  Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma Business Wire
Oct-19-18 10:10AM  Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC Business Wire
Oct-17-18 09:15AM  Stocks Jump 2%+ on Solid Earnings Zacks
Oct-12-18 08:15AM  Report: Developing Opportunities within Packaging Corporation of America, Jones Energy, Pitney Bowes, Mercury General, Invacare, and Incyte Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-11-18 10:21AM  Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales Zacks
08:00AM  Incyte to Report Third Quarter Financial Results Business Wire
Oct-09-18 07:30AM  Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress Business Wire
Oct-08-18 05:14PM  3 Top Biotech Stocks to Buy in October Motley Fool
11:15AM  Are These Beaten-Down Clinical-Stage Biotech Stocks Buys? Motley Fool
Oct-04-18 04:04PM  Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline TheStreet.com -5.36%
Sep-28-18 06:16AM  Better Buy: Geron Corporation vs. Incyte Corporation Motley Fool
Sep-26-18 03:59PM  Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance Investor's Business Daily
Sep-20-18 02:18PM  Is Incyte Corporation (NASDAQ:INCY) As Strong As Its Balance Sheet Indicates? Simply Wall St.
Sep-18-18 06:18PM  Agenus Receives Milestone Payment of $5 Million from Incyte Zacks
Sep-13-18 09:00AM  In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs) Business Wire
07:30AM  Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis Business Wire
Sep-12-18 10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks
09:11AM  Incyte, Foundation Medicine Partner for Companion Diagnostics Zacks
Sep-11-18 08:25AM  The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet Benzinga
07:30AM  Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma Business Wire
Sep-09-18 04:46PM  The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs Benzinga
Sep-07-18 01:11PM  5 Stocks To Have On Your Radar Next Week Benzinga
Sep-06-18 04:30PM  Incyte Announces Chief Financial Officer David Gryska to Retire at the End of 2018 Business Wire
11:34AM  Why Incyte Stock Gained 11% in August Motley Fool
Aug-30-18 09:49AM  Why Is Incyte (INCY) Up 12.9% Since Last Earnings Report? Zacks
Aug-29-18 02:00PM  3 Stocks That May Lead a Massive Biotech Breakout Investopedia
Aug-23-18 10:00AM  Is Agenus Inc. Stock a Buy? Motley Fool
Aug-22-18 05:32PM  Gilead paid $510M for drug and just sold it for $3 million American City Business Journals
Aug-21-18 03:40PM  Incyte Has Quietly Risen 13 Percent In The Last Two Weeks, And That Uptrend Looks Like It Will Continue Benzinga
Aug-10-18 07:45AM  New Research: Key Drivers of Growth for United Rentals, DISH Network, Terex, Plains Group Holdings, The Hain Celestial Group, and Incyte Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-08-18 06:00AM  10 Undervalued Stocks With 'Exponential' Growth Potential Morningstar
Aug-06-18 04:00PM  This stock sector most often beats analysts estimates MarketWatch
06:54AM  3 Big Stock Charts for Monday: Entergy, Incyte and SL Green Realty InvestorPlace
Aug-01-18 01:24PM  Edited Transcript of INCY earnings conference call or presentation 31-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
07:00AM  Incyte's Outlook Boosted by Robust Pipeline Morningstar
Jul-31-18 04:00PM  Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2 Zacks
08:30AM  Incyte (INCY) Lags Q2 Earnings Estimates Zacks
07:26AM  Incyte: 2Q Earnings Snapshot Associated Press
07:00AM  Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs Business Wire
06:00AM  Incyte Corporation to Host Earnings Call ACCESSWIRE
Jul-30-18 12:09PM  Could Gilead Merge With Pfizer Or Vertex To Solve Its CEO Problem? Investor's Business Daily
09:49AM  Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT Zacks
Jul-27-18 08:01AM  Incyte (INCY) to Report Q2 Earnings: What's in the Cards? Zacks
Jul-26-18 06:32AM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation Motley Fool
Jul-24-18 01:25PM  NYSE trader: Amazon, Visa and Twitter earnings are on my radartheir charts are very similar Yahoo Finance Video
Jul-20-18 03:00PM  10 Cancer-Fighting Health Care Stocks to Buy Kiplinger
Jul-19-18 06:30PM  Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE) PR Newswire
11:14AM  CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA Zacks
09:38AM  Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2? Zacks
08:46AM  The 3 Worst Healthcare Stocks of 2018 (So Far) Motley Fool
Jul-15-18 03:42PM  Benzinga's Bulls & Bears Of The Week: AT&T, Facebook, Intel, Netflix, Twitter And More Benzinga
Jul-13-18 10:16AM  Incyte Has Limited Catalysts In Next 6 Months; But 2019 Could Be Pivotal, Morgan Stanley Says In Downgrade Benzinga
Jul-12-18 08:00AM  Incyte to Report Second Quarter Financial Results Business Wire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naive acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESDirectorNov 08Buy68.771,00068,7656,668Nov 09 04:21 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Option Exercise18.3210,000183,20042,324Oct 05 04:29 PM
Trower PaulPrincipal Accounting OfficerOct 03Option Exercise17.7910,000177,90024,172Oct 05 04:30 PM
Trower PaulPrincipal Accounting OfficerOct 03Sale70.0010,000700,00014,172Oct 05 04:30 PM
SWAIN PAULA JEVP, Human ResourcesOct 03Sale70.0010,000700,00032,324Oct 05 04:29 PM
Flannelly Barry PEVP & General Manager USOct 03Sale70.001,00070,00012,427Oct 05 04:23 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Option Exercise18.3210,000183,20042,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesSep 04Sale73.2110,000732,10032,324Sep 06 04:30 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Option Exercise18.3210,000183,20042,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesAug 21Sale70.0010,000700,00032,324Aug 22 04:02 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Option Exercise18.3210,000183,20042,963Jul 11 04:41 PM
SWAIN PAULA JEVP, Human ResourcesJul 09Sale71.1110,000711,10032,963Jul 11 04:41 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJul 09Sale71.3460643,2328,103Jul 11 04:39 PM
BROOKE PAUL ADirectorJun 04Option Exercise2.8020,00056,000217,859Jun 06 04:33 PM
BAKER BROS. ADVISORS LPDirectorMay 02Option Exercise9.9260,000595,20029,267,937May 03 04:19 PM
Hoppenot HerveChairman / CEOMay 02Buy60.9415,000914,100276,690May 03 05:05 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Option Exercise17.7980,0001,423,200107,267May 02 05:04 PM
SWAIN PAULA JEVP, Human ResourcesApr 30Sale62.4380,0004,994,40033,367May 02 05:04 PM
BROOKE PAUL ADirectorApr 05Option Exercise9.9220,000198,400217,859Apr 09 05:01 PM
GRYSKA DAVID WExecutive Vice President, CFOFeb 21Sale85.561,952167,01310,970Feb 22 04:46 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 21Sale85.551,958167,50735,183Feb 22 04:23 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Option Exercise83.836,760566,69120,752Jan 09 04:09 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Sale98.876,760668,36113,992Jan 09 04:09 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Option Exercise72.865,000364,30013,676Jan 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Sale97.265,000486,3008,676Jan 03 04:32 PM